Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interaction Study of MK-8507 and Islatravir
NCT06619678Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ulonivirine and islatravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity of Islatravir Metabolite up to 43 days, Area Under the Concentration-Time Curve from Time 0 to 168 hours of Islatravir Metabolite and 19 more. Started Jan 2024; status: completed.
02
Drugs
ulonivirineislatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06619678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619678.